Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -0.1x - -0.1x | -0.1x |
| Selected Fwd P/E Multiple | 0.0x - 0.0x | 0.0x |
| Fair Value | $8.73 - $9.65 | $9.19 |
| Upside | 27.4% - 40.8% | 34.1% |
| Benchmarks | - | Full Ticker |
| Orgenesis Inc. | - | OTCPK:ORGS |
| Curis, Inc. | - | NasdaqCM:CRIS |
| I-Mab | - | NasdaqGM:IMAB |
| XOMA Royalty Corporation | - | NasdaqGM:XOMA |
| Karyopharm Therapeutics Inc. | - | NasdaqGS:KPTI |
| Aditxt, Inc. | - | NasdaqCM:ADTX |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| ORGS | CRIS | IMAB | XOMA | KPTI | ADTX | |||
| OTCPK:ORGS | NasdaqCM:CRIS | NasdaqGM:IMAB | NasdaqGM:XOMA | NasdaqGS:KPTI | NasdaqCM:ADTX | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 34.9% | 3.3% | 95.2% | 58.3% | 46.6% | -55.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -1533.1% | -416.4% | -3504.4% | -227.9% | -123.2% | -10879.8% | ||
| Prior Fiscal Year | -41.3% | -557.7% | 1131.6% | -973.2% | -98.0% | -2965.3% | ||
| Latest Fiscal Year | -10445.5% | -473.0% | -5302.0% | -67.7% | -52.6% | -5068.5% | ||
| Latest Twelve Months | -3827.8% | -443.3% | -15495.7% | -67.7% | -52.6% | -21804.0% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -1.3x | -0.8x | 1.8x | -7.4x | -1.7x | -0.4x | ||
| Price / LTM Sales | 16.0x | 2.0x | 119.5x | 8.9x | 0.3x | 10.2x | ||
| LTM P/E Ratio | -0.4x | -0.4x | -0.8x | -13.1x | -0.5x | 0.0x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -13.1x | -0.5x | -0.4x | |||||
| Historical LTM P/E Ratio | -0.4x | -0.1x | 0.0x | |||||
| Selected P/E Multiple | -0.1x | -0.1x | -0.1x | |||||
| (x) LTM Net Income | (46) | (46) | (46) | |||||
| (=) Equity Value | 3 | 3 | 3 | |||||
| (/) Shares Outstanding | 0.3 | 0.3 | 0.3 | |||||
| Implied Value Range | 8.51 | 8.96 | 9.41 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 8.51 | 8.96 | 9.41 | 6.85 | ||||
| Upside / (Downside) | 24.3% | 30.8% | 37.4% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | ORGS | CRIS | IMAB | XOMA | KPTI | ADTX | |
| Value of Common Equity | 17 | 20 | 68 | 253 | 41 | 2 | |
| (/) Shares Outstanding | 5.4 | 8.5 | 81.4 | 12.0 | 8.4 | 0.3 | |
| Implied Stock Price | 3.20 | 2.39 | 0.84 | 21.13 | 4.85 | 6.85 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 3.20 | 2.39 | 0.84 | 21.13 | 4.85 | 6.85 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |